Intellia Therapeutics (NTLA) Q2 FY26 earnings call

Intellia Therapeutics reported strong Q2 FY26 results, highlighted by positive Phase III data for lonvo-z in HAE, positioning it for a potential H1 2027 launch. The company also resumed enrollment in its nex-z ATTR trials and identified a genetic marker for transaminase elevations, enhancing patient management. Financials reflect ongoing R&D and commercial build-out, with a solid cash runway.